US 12,404,255 B2
Compound and pharmaceutical composition containing same for treating or preventing neural damage, neural disease, or developmental disorder through promoting proliferation, differentiation, and/or regeneration of neural cells
Sha Joung Chang, Seongnam-si (KR); Yeoun Hee Kim, Daegu (KR); Jung Jin Lee, Daegu (KR); Ga Ram Choi, Daegu (KR); and Yong Min Chang, Daegu (KR)
Assigned to ETNOVA THERAPEUTICS CORP, Seongnam (KR); and KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, Daegu (KR)
Appl. No. 17/999,337
Filed by ETNOVA THERAPEUTICS CORP., Seongnam-si (KR); and KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, Daegu (KR)
PCT Filed Aug. 25, 2020, PCT No. PCT/KR2020/011305
§ 371(c)(1), (2) Date Nov. 18, 2022,
PCT Pub. No. WO2021/251551, PCT Pub. Date Dec. 16, 2021.
Claims priority of application No. 10-2020-0071638 (KR), filed on Jun. 12, 2020.
Prior Publication US 2023/0183192 A1, Jun. 15, 2023
Int. Cl. C07D 257/02 (2006.01)
CPC C07D 257/02 (2013.01) 7 Claims
 
1. A compound represented by a following Chemical Formula 1:

OG Complex Work Unit Chemistry
wherein in the Chemical Formula 1,
each of R1 to R3 independently represents hydrogen, linear or branched (C1-C10)alkyl, or an electron pair to form any bond,
A represents *—(CH2)n-A1-*,
n represents any integer from 0 to 5,
A1 represents *—COO—*, *—CO—*, *—NR4—*, *—CH2—*, *—CONH—*, or *—O—*,
Linker represents *-L1-NHCO-L2-*, *-L1-O—R—O-L2-*, *-L1-CH2-L2-*, *-L1-NR5-L2-*, or *-L1-COO-L2-*,
L1 represents linear or branched (C1-C30)alkyl,
L2 represents a single bond or linear or branched (C1-C30)alkyl,
R represents linear or branched (C1-C20)alkyl,
each of R4 and R5 independently represents hydrogen or linear or branched (C1-C10)alkyl, and
B represents a moiety derived from retinoic acid.